Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy

Annals of Oncology

Volumn 10, Issue SUPPL. 2, 1999, Pages

  Krenning, E P ^b   De Jong, M ^c   Kooij, P P M ^c   Breeman, W A P ^c   Bakker, W H ^c   De Herder, W W ^c   Van Eijck, C H J ^c   Kwekkeboom, D J ^c   Jamar, F ^a   Pauwels, S ^a   Valkema, R ^c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NONE

Author keywords

Octreotide; Peptide; Radionuclide; Scintigraphy; Somatostatin; Therapy

Indexed keywords

PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; YTTRIUM 90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; NEUROENDOCRINE TUMOR; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY; RAT; SCINTIGRAPHY; THROMBOCYTE COUNT; TUMOR VOLUME;

EID: 13744265578     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_2.S23     Document Type: Conference Paper

References (29)

1. Yamada Y, Kagimoto S, Kubota A et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin subtype. Biochem Biophys Res Commun 1993; 195 (2): 844-52.
2. Bruno JF, Berelowitz M. Somatostatin receptors: Orphan that found family and function. Mol Cell Neurosci 1993; 4: 307-9.
3. Rohrer L, Raulf F, Bruns C et al. Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 1993; 90: 4196-200.
4. Kubota A, Yamada Y, Kagimoto S et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS-201-995 in treatment of human endocrine tumors. J Clin Invest 1994; 93: 1321-5.
5. Breeman WA, VanHagen MP, Visser-Wisselaar HA et al. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. J Nucl Med 1996; 37: 108-17.
6. 3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-31.
7. Krenning EP, Kwekkeboom DJ, Pauwels S et al. Somatostatin receptor scintigraphy. In Freeman LM (ed): Nuclear Medicine Annual. New York: Raven Press 1995; 1-50.
8. Virgolini I, Raderer M, Kurtaran et al. Vasoactive intestinal peptide receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331: 1116-21.
9. Schwarz AL, Fridovich SE, Lodisch HF. Kinetics of internalization and recycling of the asialoglycoprotein receptor in hepatoma cell line. J Biol Chem 1982; 257: 4230-7.
10. Weigel PH. Mechanisms of cellular processing and degradation of internalized soluble glycoproteins. In Allen HJ, Kisaulis EC (eds): Glycoconjugates, Composition, Structure and Function. New York: Marcel Dekker 1992.
11. Duncan JR, Stephenson MT, Wu HP et al. Indium-111-diethylene-triaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997; 57 (4): 659-71.
12. Andersson P, Forssel-Aronsson E, Johanson V et al. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med 1996; 37: 2002-6.
13. 3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998; 19: 283-8.
14. 1]-octreotide. A case history. Ann NY Acad Sci 1994; 733: 496-506.
15. Krenning EP, Kooij PPM, Pauwels S et al. Somatostatin receptor: Scintigraphy and radionuclide therapy. Digestion 1996; 57 (Suppl): 57-61.
16. Gibril F, Reynolds JC, Doppman JL et al. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996; 125: 26-34.
17. Termanini B, Gibril F, Reynolds JC et al. Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112: 335-47.
18. Bambyrek W, Craseman B, Fink WR. X-ray fluorescence yields, Auger, and Coster-Kronig transition possibilities. Rev Phys 1972; 44: 716-813.
19. Howell RW. Radiation spectra for Auger electron emitting radionuclides. Report No. 2 of AAPM Nuclear Medicine Task Group. Med Phys 1992; 19: 1371-83.
20. Adelstein SJ. The Auger process: A therapeutic promise? AJR 1993; 160; 707-13.
21. Fjalling M, Andersson P, Forssell-Aronsson E et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phel-octreotide in midgut carcinoid syndrome. J Nucl Med 1996; 37: 1519-21.
22. 1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation. Life Sci 1991; 49: 1583-91.
23. 3]octreotide. J Nucl Med 1992; 33: 652-8.
24. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24: 368-71.
25. Otte A, Jermann E, Behe M et al. Dotatoc: A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24: 792-5.
26. Otte A, Mueller-Brand J, Dellas S et al. Yttrium-90 labelled somatostatin analogue for cancer treatment. Lancet 1998; 351: 417-8.
27. Jong de M, Rolleman EJ, Bernard BF et al. Inhibition of renal uptake of Indium-111-DTPA-octreotide in vivo. J Nucl Med 1996; 37: 1388-92.
28. Bernard HF, Krenning EP, Breeman WAP et al. D-lysine reduction of Indium-111 octreotide and Yttrium-90 octreotide renal uptake. J Nucl Med 1997; 38 (12): 1929-34.
29. Mogensen CE, Solling K. Studies on renal tubular protein reabsorption: Partial and near complete inhibition by certain amino acids. Scan J Clin Lab Invest 1977; 37: 477-86.